V. Fiorelli

发表

HIV-1 infection and the developing nervous system: lineage-specific regulation of viral gene expression and replication in distinct neuronal precursors.

C. Thiele, F. Ensoli, H. Wang, 1997, Journal of neurovirology.

Basic fibroblast growth factor supports human olfactory neurogenesis by autocrine/paracrine mechanisms

C. Thiele, B. Ensoli, F. Ensoli, 1998, Neuroscience.

Plasma viraemia in seronegative HIV-1-infected individuals.

F. Ensoli, V. Fiorelli, G. Luzi, 1991, AIDS.

Silent HIV infection.

F. Ensoli, V. Fiorelli, I. Mezzaroma, 1993, Vaccine.

HIV-1 Tat Addresses Dendritic Cells to Induce a Predominant Th1-Type Adaptive Immune Response That Appears Prevalent in the Asymptomatic Stage of Infection

M. Magnani, A. Scoglio, S. Moretti, 2009 .

Effects of cytokines from activated immune cells on vascular cell growth and HIV-1 gene expression. Implications for AIDS-Kaposi's sarcoma pathogenesis.

L. Buonaguro, R. Gallo, G. Barillari, 1992, Journal of immunology.

The preventive phase I trial with the HIV-1 Tat-based vaccine.

G. D'offizi, P. Narciso, A. Lazzarin, 2009, Vaccine.

Parallel conduction of the phase I preventive and therapeutic trials based on the Tat vaccine candidate.

G. D'offizi, P. Narciso, A. Lazzarin, 2009, Reviews on recent clinical trials.

Phase I therapeutic trial of the HIV-1 Tat protein and long term follow-up.

G. D'offizi, P. Narciso, A. Lazzarin, 2009, Vaccine.

Mucosal delivery of the human immunodeficiency virus-1 Tat protein in mice elicits systemic neutralizing antibodies, cytotoxic T lymphocytes and mucosal IgA.

M. Marinaro, R. Rappuoli, M. Pizza, 2003, Vaccine.

HIV-1 Tat-based vaccines: from basic science to clinical trials.

M. Magnani, A. Scoglio, S. Moretti, 2002, DNA and cell biology.

Circulating stem cell vary with NYHA stage in heart failure patients

R. Ferrari, C. Beltrami, A. Fucili, 2011, Journal of cellular and molecular medicine.

IFN-gamma induces endothelial cells to proliferate and to invade the extracellular matrix in response to the HIV-1 Tat protein: implications for AIDS-Kaposi's sarcoma pathogenesis.

P. Monini, G. Barillari, B. Ensoli, 1999, Journal of immunology.

The Tat protein of human immunodeficiency virus type-1 promotes vascular cell growth and locomotion by engaging the alpha5beta1 and alphavbeta3 integrins and by mobilizing sequestered basic fibroblast growth factor.

G. Barillari, B. Ensoli, V. Fiorelli, 1999, Blood.

gamma-Interferon produced by CD8+ T cells infiltrating Kaposi's sarcoma induces spindle cells with angiogenic phenotype and synergy with human immunodeficiency virus-1 Tat protein: an immune response to human herpesvirus-8 infection?

P. Monini, R. Gallo, B. Ensoli, 1998, Blood.

Block of AIDS-Kaposi's sarcoma (KS) cell growth, angiogenesis, and lesion formation in nude mice by antisense oligonucleotide targeting basic fibroblast growth factor. A novel strategy for the therapy of KS.

M. Raffeld, G. Zon, R. Gallo, 1994, The Journal of clinical investigation.

Distribution of the natural killer-related receptor for HLA-C during highly active antiretroviral therapy for human immunodeficiency virus infection.

S. Topino, F. Ensoli, V. Fiorelli, 2001, Human immunology.

γ-Interferon Production in Peripheral Blood Mononuclear Cells and Tumor Infiltrating Lymphocytes From Kaposi's Sarcoma Patients: Correlation With the Presence of Human Herpesvirus-8 in Peripheral Blood Mononuclear Cells and Lesional Macrophages

S. Topino, S. Uccini, A. Angeloni, 1998 .

gamma-Interferon production in peripheral blood mononuclear cells and tumor infiltrating lymphocytes from Kaposi's sarcoma patients: correlation with the presence of human herpesvirus-8 in peripheral blood mononuclear cells and lesional macrophages.

S. Topino, S. Uccini, A. Angeloni, 1998, Blood.

Vaccines based on the native HIV Tat protein and on the combination of Tat and the structural HIV protein variant DeltaV2 Env.

M. Magnani, R. Gavioli, A. Caputo, 2005, Microbes and infection.

The presence of anti-Tat antibodies is predictive of long-term nonprogression to AIDS or severe immunodeficiency: findings in a cohort of HIV-1 seroconverters.

M. Ciccozzi, A. Scoglio, A. Caputo, 2005, The Journal of infectious diseases.

Immune-derived cytokines in the nervous system: epigenetic instructive signals or neuropathogenic mediators?

S. Topino, F. Ensoli, V. Fiorelli, 1999, Critical reviews in immunology.

Decreased T cell apoptosis and T cell recovery during highly active antiretroviral therapy (HAART).

F. Ensoli, V. Fiorelli, M. De Cristofaro, 2000, Clinical immunology.

Proviral sequences detection of human immunodeficiency virus in seronegative subjects by polymerase chain reaction.

F. Ensoli, V. Fiorelli, I. Mezzaroma, 1990, Molecular and cellular probes.

Cytokines from activated T cells induce normal endothelial cells to acquire the phenotypic and functional features of AIDS-Kaposi's sarcoma spindle cells.

B. Ensoli, V. Fiorelli, R. Gendelman, 1995, The Journal of clinical investigation.

Synergy between basic fibroblast growth factor and HIV-1 Tat protein in induction of Kaposi's sarcoma

M. Raffeld, J. Brady, R. Gallo, 1994, Nature.

Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation

P. Wingfield, L. Buonaguro, R. Morgan, 1993, Journal of virology.

New developments: a look to the future.

R. Gallo, B. Ensoli, V. Fiorelli, 1996, Oncology.

Sequence conservation and antibody cross-recognition of clade B human immunodeficiency virus (HIV) type 1 Tat protein in HIV-1-infected Italians, Ugandans, and South Africans.

M. Colvin, M. Ciccozzi, A. Scoglio, 2003, The Journal of infectious diseases.

Long-term protection against SHIV89.6P replication in HIV-1 Tat vaccinated cynomolgus monkeys.

J. Heeney, M. Ciccozzi, A. Scoglio, 2004, Vaccine.

Long-term protection against SHIV 89 . 6 P replication in 3 HIV-1 Tat vaccinated cynomolgus monkeys 4

J. Heeney, M. Ciccozzi, A. Scoglio, 2004 .

Candidate HIV-1 Tat vaccine development: from basic science to clinical trials.

M. Magnani, P. Monini, A. Caputo, 2006, AIDS.

Red blood cell-mediated delivery of recombinant HIV-1 Tat protein in mice induces anti-Tat neutralizing antibodies and CTL.

M. Magnani, A. Scoglio, S. Dominici, 2003, Vaccine.

HTLV-I ANTIBODIES AND LYMPHOPROLIFERATIVE DISEASE OF GRANULAR LYMPHOCYTES

T. Chisesi, V. Fiorelli, R. Zambello, 1987, The Lancet.

The therapeutic phase I trial of the recombinant native HIV-1 Tat protein

P. Narciso, A. Lazzarin, M. Magnani, 2008, AIDS.

Role of immune-derived diffusible mediators in AIDS-associated neurological disorders.

F. Ensoli, V. Fiorelli, M. De Cristofaro, 2000, Archivum immunologiae et therapiae experimentalis.

HIV-1 infection of primary human neuroblasts.

C. Thiele, B. Ensoli, F. Ensoli, 1995, Virology.

Prophylactic and therapeutic phase I trials with the active Tat protein vaccine: results of the interim analysis

It Istituto Superiore di Sanit, A. Carlo, P. Narciso, 2006 .

Inflammatory cytokines and HIV-1-associated neurodegeneration: oncostatin-M produced by mononuclear cells from HIV-1-infected individuals induces apoptosis of primary neurons.

C. Thiele, F. Ensoli, V. Fiorelli, 1999, Journal of immunology.

Lymphomononuclear cells from multiple sclerosis patients spontaneously produce high levels of oncostatin M, tumor necrosis factors α and β, and interferon γ

A. Lugaresi, F. Ensoli, V. Fiorelli, 2002 .

HIV-1 Tat Addresses Dendritic Cells to Induce a Predominant Th1-Type Adaptive Immune Response That Appears Prevalent in the Asymptomatic Stage of Infection1

M. Magnani, A. Scoglio, S. Moretti, 2009, The Journal of Immunology.

Efficient systemic and mucosal responses against the HIV-1 Tat protein by prime/boost vaccination using the lipopeptide MALP-2 as adjuvant.

B. Ensoli, T. Ebensen, C. Guzmán, 2006, Vaccine.

the Asymptomatic Stage of Infection Immune Response That Appears Prevalent in Induce a Predominant Th1-Type Adaptive HIV-1 Tat Addresses Dendritic Cells to

M. Magnani, A. Scoglio, S. Moretti, 2009 .

Forum in immunology Vaccines based on the native HIV Tat protein and on the combination of Tat and the structural HIV protein variant DV2 Env

M. Magnani, R. Gavioli, A. Caputo, 2005 .

Efficient mucosal delivery of the HIV‐1 Tat protein using the synthetic lipopeptide MALP‐2 as adjuvant

A. Scoglio, F. Nappi, B. Ensoli, 2003, European journal of immunology.

The therapeutic phase I trial of the recombinant native HIV-1 Tat protein

P. Narciso, A. Lazzarin, M. Magnani, 2008, AIDS (London).

Red blood cell-mediated delivery of recombinant HIV-1 Tat protein in mice induces anti-Tat neutralizing antibodies and CTL.

A. Scoglio, S. Dominici, A. Caputo, 2003, Vaccine.

The therapeutic phase I trial of the recombinant native HIV-1 Tat protein

D. Burton, R. Dwek, D. Dunlop, 2008, AIDS.

CCR5 and CXCR4 chemokine receptor expression and β‐chemokine production during early T cell repopulation induced by highly active anti‐retroviral therapy

V. Fiorelli, A. Giovannetti, M. Pierdominici, 1999, Clinical and experimental immunology.